Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S2213-2600(24)00420-X | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
, a R2R3-MYB transcription factor from purple tea (), positively regulates anthocyanin biosynthesis.
Front Plant Sci
December 2024
Tea Research Institute, Guangdong Academy of Agricultural Sciences, Guangdong Provincial Key Laboratory of Tea Plant Resources Innovation and Utilization, Guangzhou, Guangdong, China.
In tea (), anthocyanins are important secondary metabolites that are linked to leaf color. Anthocyanin biosynthesis is a complex biological process, in which multiple genes including structural and regulatory genes are involved. Here, we describe the cloning and characterizing of a new R2R3-MYB transcription factor gene, , isolated from purple tea variety ''.
View Article and Find Full Text PDFThe New Cardiovascular-Kidney-Metabolic (CKM) Syndrome: An Opportunity for CKD Detection and Treatment in Primary Care.
Am J Kidney Dis
December 2024
San Francisco VA Health Care System, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Kidney Health Research Collaborative, San Francisco, CA. Electronic address:
In October of 2023, the American Heart Association (AHA) published a scientific statement and advisory that defined a novel entity, the Cardiovascular-Kidney-Metabolic (CKM) Syndrome. The overall framework proposes that a substantial proportion of cardiovascular disease (CVD) burden is attributable to a syndrome that extends in stages from: Stage 1) obesity, Stage 2) metabolic/kidney risk factors for CVD (diabetes mellitus, chronic kidney disease (CKD), hypertension, and dyslipidemia), Stage 3) subclinical CVD, and finally Stage 4) clinical CVD. The report that describes the CKM paradigm documents the scientific justification for a syndrome, highlights the overlap in risk factors among individuals with obesity, diabetes, CKD, and CVD, and aligns the evidence and guideline statements that address screening, prevention, and management of these conditions.
View Article and Find Full Text PDFPembrolizumab versus sintilimab in patients with advanced NSCLC: a retrospective multicenter study with propensity-score matching analysis.
Front Oncol
December 2024
Department of Pharmacy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Programmed cell death protein 1 (PD-1) inhibitors are commonly used worldwide for the management of non-small cell lung cancer (NSCLC). However, it remains unclear whether pembrolizumab and sintilimab, two of the most widely used PD-1 inhibitors in China, have significantly different effects on patients with NSCLC. A multicenter retrospective cohort study was designed and implemented using propensity-score matching (PSM) analysis to compare the effectiveness and safety profiles of pembrolizumab and sintilimab in patients with advanced NSCLC undergoing comprehensive therapy.
View Article and Find Full Text PDFa novel marker associated with poor pediatric AML outcomes that affect the fatty acid synthesis and cell cycle pathways.
Front Oncol
December 2024
Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, United States.
Introduction: Despite remarkable progress in Pediatric Acute Myeloid Leukemia (pAML) treatments, the relapsed disease remains difficult to treat, making it pertinent to identify novel biomarkers of prognostic/therapeutic significance.
Material And Methods: Bone marrow samples from 21 pAML patients were analyzed using single cell RNA sequencing, functional assays with knockdown and overexpression were performed in leukemia cell lines to evaluate impact on proliferation and migration, and chemotherapy sensitivity. Mitochondrial function was assessed via Seahorse assay, interacting proteins were studied using co-immunoprecipitation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!